ArticleEJNMMI research2023
Accuracy and uncertainty analysis of reduced time point imaging effect on time-integrated activity for
Article in EJNMMI research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Outcome-driven dosimetry optimization for [European journal of nuclear medicine and molecular imaging · 2026Article
- Validation of Simplified Renal Dosimetry Protocols forMolecular imaging and radionuclide therapy · 2026Article
- Review
- [EJNMMI physics · 2026Article
- Towards practical radiopharmaceutical treatment planning: a review of dosimetry simplification techniques.Theranostics · 2026Review
- Understanding time-activity curve and time-integrated activity variations in radiopharmaceutical therapy challenge: Experience and results.Medical physics · 2025Article
- Characterization of Effective Half-Life for Instant Single-Time-Point Dosimetry Using Machine Learning.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Accuracy and precision analyses of single-time-point dosimetry utilising physiologically-based pharmacokinetic modelling and non-linear mixed-effects modelling.EJNMMI physics · 2025Article
- On the reduction of imaging time-points for dosimetry in radionuclide therapy.EJNMMI physics · 2025Article
- Linear Boltzmann equation solver for voxel-level dosimetry in radiopharmaceutical therapy: Comparison with Monte Carlo and kernel convolution.Medical physics · 2024Article
- Impact of the Reference Multiple-Time-Point Dosimetry Protocol on the Validity of Single-Time-Point Dosimetry for [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Estimation of kidney doses from [EJNMMI physics · 2024Article
- A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?EJNMMI physics · 2024Review
- Organ and tumor dosimetry including method simplification for [EJNMMI physics · 2024Article
- Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Activity quantification and dosimetry in radiopharmaceutical therapy with reference toFrontiers in nuclear medicine · 2024Review
Corrections and comments
- Update of
Authors and funding
3 authors.
Funding
Abstract
backgroundDosimetry promises many advantages for radiopharmaceutical therapies but repeat post-therapy imaging for dosimetry can burden both patients and clinics. Recent applications of reduced time point imaging for time-integrated activity (TIA) determination for internal dosimetry following
methodsThe study includes 28 patients with gastroenteropancreatic neuroendocrine tumors who underwent post-therapy SPECT/CT imaging at approximately 4, 24, 96, and 168 h post-therapy (p.t.) following the first cycle of
resultsThe optimal post-therapy imaging time period for STP estimates of TIA was found to be 3-5 days (71-126 h) p.t. for tumor and organs, with one exception of 6-8 days (144-194 h) p.t. for spleen with one STP approach. At the optimal time point, STP estimates give mean percent errors (MPE) within ± 5% and SD < 9% across all structures with largest magnitude error for kidney TIA (MPE = - 4.1%) and highest variability also for kidney TIA (SD = 8.4%). The optimal sampling schedule for 2TP estimates of TIA is 1-2 days (21-52 h) p.t. followed by 3-5 days (71-126 h) p.t. for kidney, tumor, and spleen. Using the optimal sampling schedule, the largest magnitude MPE for 2TP estimates is 1.2% for spleen and highest variability is in tumor with SD = 5.8%. The optimal sampling schedule for 3TP estimates of TIA is 1-2 days (21-52 h) p.t. followed by 3-5 days (71-126 h) p.t. and 6-8 days (144-194 h) p.t. for all structures. Using the optimal sampling schedule, the largest magnitude MPE for 3TP estimates is 2.5% for spleen and highest variability is in tumor with SD = 2.1%. Simulated patient results corroborate these findings with similar optimal sampling schedules and errors. Many sub-optimal reduced time point sampling schedules also exhibit low error and variability.
conclusionsWe show that reduced time point methods can be used to achieve acceptable average TIA errors over a wide range of imaging time points and sampling schedules while maintaining low uncertainty. This information can improve the feasibility of dosimetry for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.